Century Therapeutics (IPSC) Operating Income (2020 - 2026)

Century Therapeutics (IPSC) has reported Operating Income for 7 consecutive years, with -$23.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income fell 131.93% year-over-year to -$23.7 million; the TTM figure through Mar 2026 stood at -$115.1 million (down 252.58% YoY), while the FY2025 annual figure was -$17.3 million, up 87.5% from the prior year.
• Operating Income retreated to -$23.7 million in Q1 2026 per IPSC's latest filing, from -$20.7 million in the prior quarter.
• Across five years, Operating Income topped out at $74.2 million in Q1 2025 and bottomed at -$43.8 million in Q4 2023.
• Historically, Operating Income has averaged -$27.0 million across 5 years, with a median of -$34.7 million in 2025.
• Annual changes were most pronounced in 2025 — Operating Income soared 336.92% — and 2026, when it sank 131.93%.
• Century Therapeutics' Operating Income stood at -$33.3 million in 2022, then sank by 31.39% to -$43.8 million in 2023, then advanced by 14.8% to -$37.3 million in 2024, then jumped by 44.61% to -$20.7 million in 2025, then fell by 14.69% to -$23.7 million in 2026.
• Business Quant data shows IPSC's Operating Income at -$23.7 million in Q1 2026, -$20.7 million in Q4 2025, and -$36.1 million in Q3 2025.